Resources

KPT-0127 Induces Selective Apoptosis of Malignant Cells by CRM1 Inhibition and Elevation of Regulatory Proteins p53, p21, FOXO and IkB

• PDF (1.31 MB)

Selective inhibitors of Nuclear Export (SINE) Block the Expression of DNA Damage Repair Proteins and Sensitize Cancer Cells to DNA Damage Inducing Therapeutic Agents

• PDF (5.80 MB)

Nuclear Import and Export Inhibitors Alter New World Alphavirus Capsid Localization and Reduce Viral Replication in Mammalian Cells

• PDF (603.86 KB)

Preclinical and Early Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Exportin 1 (XPO1) Antagonist Selinexor (KPT-330) in Patients (pts) with Platinum Resistant/Refractory Ovarian Cancer (OvCa)

• PDF (3.50 MB)

Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Head & Neck Squamous Cell Carcinoma (HN-SCC)

• PDF (3.11 MB)

Selinexor (KPT-330), an Oral, Selective Inhibitor of Nuclear Export (SINE) Shows Anti-Prostate Cancer (PrCa) Activity Preclinically & Disease Control in Patients (pts) with Chemotherapy Refractory, Castrate-Resistant Prostate Cancer (CRPC)

• PDF (2.86 MB)

Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells

• External Link

Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer

• External Link

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines

• External Link

Verdinexor, a novel Selective Inhibitor of Nuclear Export (SINE), reduces Influenza A virus replication in vitro and in vivo.

• External Link